IBD risk loci are enriched in multigenic regulatory modules encompassing putative causative genesYukihide Momozawa, Judy H. Cho, Christelle Lecut et al.|Nature Communications|2018Cited by 252
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, C. Janneke van der Woude, Gerard Dijkstra et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129
Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort StudiesMirjam Severs, Herma H. Fidder, Lieke M. Spekhorst et al.|Inflammatory Bowel Diseases|2018Cited by 103
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registryVince Biemans, Jasmijn A M Sleutjes, Annemarie C. de Vries et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 87
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of lifeShannon L. Kanis, C. Janneke van der Woude, Sanne Modderman et al.|Gut|2020Cited by 81